P. Gineste

发表

Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study

K. Ruxrungtham, D. Scherrer, H. Ehrlich, 2017, Antimicrobial Agents and Chemotherapy.

Low anti‐HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen‐negative patients

H. Wedemeyer, B. Maasoumy, B. Bremer, 2022, Liver international : official journal of the International Association for the Study of the Liver.

Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients

M. Manns, P. Tangkijvanich, H. Wedemeyer, 2018, The Journal of infectious diseases.

Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg‐Negative CHB

H. Wedemeyer, S. Binder, C. Falk, 2020, Hepatology communications.

Mast cell leukemia: identification of a new c‐Kit mutation, dup(501‐502), and response to masitinib, a c‐Kit tyrosine kinase inhibitor

E. Macintyre, P. Dubreuil, A. Aouba, 2012, European journal of haematology.

Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study

D. Scherrer, H. Ehrlich, J. Tazi, 2019, Journal of virus eradication.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

X. Mariette, P. Dubreuil, J. Sibilia, 2009, Arthritis research & therapy.

ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.

H. Tilg, S. Vermeire, D. Scherrer, 2022, The lancet. Gastroenterology & hepatology.

Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: Results of phase 2a trial.

H. Tilg, S. Vermeire, X. Hébuterne, 2021, Gastroenterology.

Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects

D. Scherrer, H. Ehrlich, J. Tazi, 2016, The Journal of antimicrobial chemotherapy.

Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects

D. Scherrer, H. Ehrlich, J. Tazi, 2016, Antimicrobial Agents and Chemotherapy.

Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study

D. Scherrer, H. Ehrlich, P. Durez, 2022, Annals of the Rheumatic Diseases.

Masitinib, a c‐kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid‐dependent asthmatics

A Magnan, I Vachier, M. Humbert, 2009, Allergy.

Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis.

H. Tilg, S. Vermeire, D. Scherrer, 2023, Journal of Crohn's & colitis.

Therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir

P. Tangkijvanich, H. Wedemeyer, C. Trépo, 2017 .

Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy

S. Sultan, O. Hermine, O. Lortholary, 2011, PloS one.

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study

P. Dubreuil, O. Hermine, O. Lortholary, 2010, American journal of hematology.

ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in Inflammatory Bowel Diseases

A. Garcel, Noëlie Campos, D. Scherrer, 2022, Clinical and translational gastroenterology.

OP21 ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients

S. Vermeire, H. Ehrlich, A. Bourreille, 2019, Journal of Crohn's and Colitis.